Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Aclaris Therapeutics, Inc. (ACRS) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/07/2023 8-K Quarterly results
06/12/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "COBRA”), Employer will continue to pay, directly to the healthcare provider when due, Employer’s portion of the medical, vision and dental coverage premiums for a period of twelve months after the effective date of Executive’s termination ; provided that, if at any time Employer determines, in its sole discretion, that the payment of the COBRA 6"
06/01/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
05/08/2023 8-K Quarterly results
04/14/2023 8-K Quarterly results
03/31/2023 8-K Regulation FD Disclosure  Interactive Data
03/27/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Amendment No. 1 to Consulting Services Agreement, by and between the Company and Frank Ruffo"
03/06/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
02/23/2023 8-K Quarterly results
01/09/2023 8-K Investor presentation
01/06/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/13/2022 8-K Quarterly results
11/22/2022 8-K Quarterly results
11/08/2022 8-K Investor presentation, Quarterly results
08/03/2022 8-K Quarterly results
08/01/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/03/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
04/13/2022 8-K Regulation FD Disclosure  Interactive Data
02/24/2022 8-K Quarterly results
01/14/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/07/2021 8-K Quarterly results
11/02/2021 8-K Quarterly results
08/27/2021 8-K Quarterly results
08/05/2021 8-K Quarterly results
07/26/2021 8-K Termination of a Material Definitive Agreement  Interactive Data
06/11/2021 8-K Quarterly results
06/08/2021 8-K Quarterly results
06/03/2021 8-K Quarterly results
05/20/2021 8-K Quarterly results
05/07/2021 8-K Quarterly results
02/25/2021 8-K Quarterly results
01/22/2021 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Other Events, Financial Statement...
Docs: "Underwriting Agreement by and among Aclaris Therapeutics, Inc., Cantor Fitzgerald & Co. and William Blair & Company, L.L.C.",
"Opinion of Cooley LLP",
"Aclaris Announces Proposed Public Offering of Common Stock WAYNE, Pa., January 19, 2021 -- Aclaris Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. All of the shares of common stock to be sold in the offering will be offered by Aclaris. Aclaris also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering on the same terms and conditions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed,...",
"Aclaris Announces Pricing of Public Offering of Common Stock WAYNE, Pa., January 20, 2021 -- Aclaris Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the pricing of its underwritten public offering of 5,483,714 shares of its common stock at a price to the public of $17.50 per share. In addition, Aclaris has granted to the underwriters a 30-day option to purchase up to 822,557 additional shares of common stock at the public offering price, less the underwriting discount. The gross proceeds from the offering to Aclaris are expected to be approximately $96.0 million, before deducting underwriting discounts and commissions and offering expenses, but excluding any exercise of the underwr..."
01/19/2021 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy